PA
TNDM icon

PharVision Advisers’s Tandem Diabetes Care TNDM Stock Holding History

PharVision Advisers’s Portfolio TNDM Stock Details TNDM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-19,554
Closed -$430K – 600
2025
Q4 		$430K Sell
19,554
-2,714
-12% -$49K 0.22% 93
2025
Q3 		$270K Buy
+22,268
New +$301K 0.15% 290

Other funds holding TNDM

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SC
Sessa Capital New York $5.51B AUM 47.23% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
ACH
ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
GKIM
GW&K Investment Management Boston, Massachusetts $11.3B AUM 31.98% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

PharVision Advisers's TNDM Position: Q1 2026 in Review

PharVision Advisers sold out of Tandem Diabetes Care (TNDM) in Q1 2026, closing a stake of 19,554 shares — an estimated $430K sold.

PharVision Advisers first reported a position in TNDM in Q3 2025 and held it in 2 quarters. The position peaked at $430K in Q4 2025. 272 funds tracked by Wall St. Rank hold TNDM as of Q1 2026.

  • PharVision Advisers reported no remaining Tandem Diabetes Care position as of Q1 2026 after selling out during the quarter.
  • PharVision Advisers sold 19,554 Tandem Diabetes Care shares in Q1 2026, an estimated $430K.
  • PharVision Advisers first reported a position in Tandem Diabetes Care in Q3 2025 and held it in 2 quarters.
  • PharVision Advisers's Tandem Diabetes Care position peaked at $430K in Q4 2025.
  • 272 funds tracked by Wall St. Rank held Tandem Diabetes Care as of Q1 2026.

Based on PharVision Advisers's 13F filing for Q1 2026, filed 22 Apr 2026.